Further modification with insertion of ICPI or co-stimulatory ligands (CTLA-4, 4-1BB, CD40-L and OX40-L) was shown to increase therapeutic efficacy in tumour-bearing mice (68). The gene discussed is CTLA4; the disease is neoplasm.